Literature DB >> 16652277

Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1.

Francis Barin1, Gonzague Jourdain, Sylvie Brunet, Nicole Ngo-Giang-Huong, Supawadee Weerawatgoompa, Warit Karnchanamayul, Surabhon Ariyadej, Rawiwan Hansudewechakul, Jullapong Achalapong, Prapap Yuthavisuthi, Chaiwat Ngampiyaskul, Sorakij Bhakeecheep, Chittaphon Hemwutthiphan, Marc Lallemant.   

Abstract

We analyzed the association between mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1) and maternal neutralizing antibodies to heterologous primary isolates of various HIV-1 clades, to test the hypothesis that protective antibodies are those with broad neutralizing activity. Our study sample included 90 Thai women for whom the timing of HIV-1 transmission (in utero or intrapartum) was known. The statistical analysis included a conditional logistic-regression model to control for both plasma viral load and duration of zidovudine prophylaxis. The higher the titer of neutralizing antibodies to a heterologous strain of the same clade, the lower the rate of MTCT of HIV-1. More specifically, high levels of neutralizing antibodies to the MBA (CRF01_AE) strain were associated with low intrapartum transmission of HIV-1. This suggested that such heterologous neutralizing antibodies may be involved in the natural prevention of late perinatal HIV transmission. These data are consistent with the hypothesis that the use of some antibodies might help to prevent perinatal HIV transmission, through passive immunoprophylaxis. Moreover, the study of humoral factors associated with MTCT of HIV-1 may identify correlates of protection that should help in the design of efficient HIV/acquired immunodeficiency syndrome vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16652277     DOI: 10.1086/503778

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.

Authors:  L Diomede; S Nyoka; C Pastori; L Scotti; A Zambon; G Sherman; C M Gray; M Sarzotti-Kelsoe; L Lopalco
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

Review 2.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 3.  Immunotherapies to prevent mother-to-child transmission of HIV.

Authors:  Mark D Hicar
Journal:  Curr HIV Res       Date:  2013-03       Impact factor: 1.581

4.  HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies.

Authors:  Genevieve G Fouda; Nicole L Yates; Justin Pollara; Xiaoying Shen; Glenn R Overman; Tatenda Mahlokozera; Andrew B Wilks; Helen H Kang; Jesus F Salazar-Gonzalez; Maria G Salazar; Linda Kalilani; Steve R Meshnick; Beatrice H Hahn; George M Shaw; Rachel V Lovingood; Thomas N Denny; Barton Haynes; Norman L Letvin; Guido Ferrari; David C Montefiori; Georgia D Tomaras; Sallie R Permar
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

5.  The breadth and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1.

Authors:  Antoine Chaillon; Thierry Wack; Martine Braibant; Laurent Mandelbrot; Stéphane Blanche; Josiane Warszawski; Francis Barin
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

6.  The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection.

Authors:  John B Lynch; Ruth Nduati; Catherine A Blish; Barbra A Richardson; Jennifer M Mabuka; Zahra Jalalian-Lechak; Grace John-Stewart; Julie Overbaugh
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

7.  Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3.

Authors:  Pushpa Jayaraman; Tuofu Zhu; Lynda Misher; Deepika Mohan; LaRene Kuller; Patricia Polacino; Barbra A Richardson; Helle Bielefeldt-Ohmann; David Anderson; Shiu-Lok Hu; Nancy L Haigwood
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  The human immunodeficiency virus type 1 envelope confers higher rates of replicative fitness to perinatally transmitted viruses than to nontransmitted viruses.

Authors:  Xiaohong Kong; John T West; Hong Zhang; Danielle M Shea; Tendai J M'soka; Charles Wood
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

9.  Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.

Authors:  Gail Ferstandig Arnold; Paola K Velasco; Andrew K Holmes; Terri Wrin; Sheila C Geisler; Pham Phung; Yu Tian; Dawn A Resnick; Xuejun Ma; Thomas M Mariano; Christos J Petropoulos; John W Taylor; Hermann Katinger; Eddy Arnold
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

10.  Sang Froid in a time of trouble: is a vaccine against HIV possible?

Authors:  Stanley A Plotkin
Journal:  J Int AIDS Soc       Date:  2009-02-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.